Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
T-PHYL vs ELIXICON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
T-PHYL is a theophylline derivative that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors.
Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.
Treatment of asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Management of chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
400 mg orally every 6 hours, or 200 mg orally every 4 hours for sustained-release.
400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.
7-9 hours in adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, or with CYP1A2 inhibitors
Terminal elimination half-life: 4-6 hours in adults; 3-4 hours in children; prolonged in hepatic impairment or congestive heart failure. Context: dosing interval adjustment required in these conditions.
Primarily hepatic via cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4; also undergoes N-demethylation and oxidation.
Primarily hepatic metabolism via cytochrome P450 1A2 (CYP1A2). Minor pathways include CYP2E1 and CYP3A4. Metabolites are excreted renally.
Renal (10% unchanged), hepatic metabolism (90%) with metabolites excreted in urine
Renal: 50% unchanged; hepatic metabolism to 3-methylxanthine, theophylline, etc. Biliary/fecal: minimal.
40% bound, primarily to albumin
Approximately 40% bound, primarily to albumin.
0.45-0.6 L/kg, approximating total body water; higher in neonates and patients with obesity
Vd: 0.3-0.5 L/kg; indicates distribution into total body water, minimal tissue binding.
Oral immediate-release: 96-100%; oral sustained-release: 80-90%
Oral immediate-release: 100%; Extended-release: 100% (well-absorbed, no first-pass metabolism).
For GFR 10-50 m L/min: administer every 8-12 hours; for GFR <10 m L/min: administer every 12-24 hours.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50% and monitor theophylline levels; GFR < 10 m L/min: reduce dose by 50% and monitor levels.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels.
Starting dose 5 mg/kg/day orally divided every 6 hours; titrate to maximum 10 mg/kg/day.
Initial: 5 mg/kg/dose orally every 6 hours; maintenance: 100-400 mg/day in divided doses; monitor levels aggressively.
Start at lowest effective dose (200 mg every 6 hours) and monitor for toxicity due to reduced clearance.
Start at lowest effective dose (e.g., 200 mg orally every 12 hours) due to reduced clearance; monitor theophylline levels and adjust based on response and tolerability.
No FDA black box warning is currently required for T-PHYL.
Theophylline has a narrow therapeutic index; plasma levels should be monitored to avoid toxicity. Dosage should be individualized based on steady-state serum concentrations. Concurrent illness, fever, or changes in smoking habits can alter theophylline clearance.
Narrow therapeutic index; monitor serum concentrations. Use with caution in patients with cardiac disorders, hepatic impairment, or peptic ulcer disease. Risk of seizures at high doses. Avoid abrupt discontinuation.
Risk of seizures at high serum levels; may induce or worsen arrhythmias; use with caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders; drug interactions with cimetidine, fluoroquinolones, macrolides, and allopurinol can increase theophylline levels.
Hypersensitivity to theophylline or any component of the formulation, concomitant use with ephedrine in children.
Hypersensitivity to theophylline or any component of the formulation; pre-existing cardiac arrhythmias (e.g., tachyarrhythmias); active seizure disorder.
High-protein foods reduce theophylline clearance; high-carbohydrate foods increase clearance. Avoid charcoal-broiled meats and caffeine-containing products (coffee, tea, cola) as they may increase toxicity. Consistency in diet is important to maintain stable serum levels.
Avoid large amounts of caffeine-containing foods and beverages such as coffee, tea, cola, and chocolate as they may increase side effects like jitteriness and insomnia. High-fat meals may affect absorption; take consistently with respect to meals. Charcoal-broiled foods may increase metabolism of theophylline, reducing efficacy.
First trimester: Possible increase in congenital malformations (e.g., cardiovascular, neural tube defects) based on animal studies and limited human data. Second/third trimester: Risk of fetal tachycardia, irritability, and neonatal withdrawal with chronic use.
Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly needed.
Excreted into breast milk in low amounts (M/P ratio ~0.3-0.5). Use with caution; monitor infant for irritability or poor feeding.
Excreted into breast milk; M/P ratio unknown. Caution advised, monitor infant for adverse effects.
Increased clearance and volume of distribution in pregnancy may require dose increase by 30-50% to maintain therapeutic levels. Monitor serum concentrations closely.
Increased clearance during pregnancy may require dose adjustment; monitor therapeutic levels.
T-PHYL (theophylline) requires therapeutic drug monitoring to maintain serum concentrations between 5-15 mcg/m L; levels >20 mcg/m L increase toxicity risk. Cigarette smoking induces its metabolism, requiring dose adjustments. Use with caution in patients with CHF, hepatic impairment, or fever, as clearance decreases. Avoid concurrent use of ciprofloxacin, cimetidine, or macrolides which can elevate levels.
ELIXICON (theophylline) requires therapeutic drug monitoring due to narrow therapeutic index of 10-20 mcg/m L. Avoid in patients with active peptic ulcer disease or seizure disorders. Use with caution in heart failure, liver disease, and elderly patients due to reduced clearance. Cigarette smoking induces metabolism, requiring dose adjustments. Common side effects include nausea, vomiting, and insomnia; toxicity presents with tachycardia, seizures, or ventricular arrhythmias.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid smoking and alcohol; these can alter theophylline levels in your blood.,Report symptoms of toxicity such as nausea, vomiting, insomnia, tremors, or rapid heartbeat.,Do not take over-the-counter medications unless approved by your doctor.,Maintain consistent dietary habits; avoid high-protein or high-carbohydrate diets that affect clearance.
Take exactly as prescribed and do not change dose without consulting your doctor.,Avoid smoking and second-hand smoke as it affects how the medication works.,Limit caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, rapid heart rate, or seizures.,Do not take this medication with other cold or asthma remedies without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about T-PHYL vs ELIXICON, answered by our medical review team.
T-PHYL is a Xanthine bronchodilator that works by T-PHYL is a theophylline derivative that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors.. ELIXICON is a Xanthine Bronchodilator that works by Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between T-PHYL and ELIXICON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of T-PHYL is: 400 mg orally every 6 hours, or 200 mg orally every 4 hours for sustained-release.. The standard adult dose of ELIXICON is: 400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between T-PHYL and ELIXICON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. T-PHYL is classified as Category C. First trimester: Possible increase in congenital malformations (e.g., cardiovascular, neural tube defects) based on animal studies and limited human data. Second/third trimester: R. ELIXICON is classified as Category C. Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.